Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | https://www.hindustanbiosciences.in/ | |
Market Cap | 3.93 Cr. | |
Enterprise Value(EV) | 6.37 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.43 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 0.72 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 5.35 | Calculated using Price: 3.83 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.03 Cr. | 10,250,800 Shares |
FaceValue | 10 | |
Company Profile | ||
Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society. |
1 Day |
|
-3.04% |
1 Week |
|
-4.01% |
1 Month |
|
-0.78% |
3 Month |
|
-18.51% |
6 Month |
|
+0.52% |
1 Year |
|
+21.97% |
2 Year |
|
+4.36% |
5 Year |
|
+447.14% |
10 Year |
|
+175.54% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -11.47 | -19.21 | -35.60 | -10.74 | -71.30 | 5.22 | 3.67 | -52.96 | -49.49 | |
Return on Capital Employed (%) | -10.57 | -16.78 | -30.17 | -8.37 | -49.03 | 2.68 | 2.40 | -23.70 | -16.66 | |
Return on Assets (%) | -10.03 | -16.51 | -30.15 | -8.42 | -47.82 | 2.37 | 1.45 | -20.83 | -16.05 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 8 | 7 | 5 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | |
Non Curr. Liab. | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | |
Curr. Liab. | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | |
Minority Int. | |||||||||||
Equity & Liab. | 10 | 8 | 6 | 6 | 4 | 6 | 6 | 3 | 3 | 3 | |
Non Curr. Assets | 8 | 7 | 5 | 5 | 3 | 4 | 3 | 2 | 2 | 2 | |
Curr. Assets | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 1 | 1 | |
Misc. Exp. not W/O | 0 | ||||||||||
Total Assets | 10 | 8 | 6 | 6 | 4 | 6 | 6 | 3 | 3 | 3 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 2 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 0 | 1 | |
Other Income | 0 | ||||||||||
Total Income | 2 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 0 | 1 | |
Total Expenditure | -3 | -2 | -1 | -1 | -3 | -3 | -2 | -2 | -1 | -1 | |
PBIDT | -1 | -1 | 0 | 0 | -2 | 0 | 0 | -1 | -1 | 0 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Taxation | 0 | 0 | 0 | ||||||||
Exceptional Items | -2 | ||||||||||
PAT | -1 | -1 | -2 | 0 | -2 | 0 | 0 | -1 | -1 | 0 | |
Adjusted EPS | -1 | -1 | -2 | 0 | -2 | 0 | 0 | -1 | -1 | 0 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | 0 | |
Cash Fr. Inv. | 0 | 0 | 0 | ||||||||
Cash Fr. Finan. | 0 | 1 | 0 | -1 | 0 | 0 | 2 | -1 | -1 | 0 | |
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tue, 31 Jan 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On 31-01-2023 Outcome of Board Meeting held on 31-01-2023 |
Sat, 21 Jan 2023
Board Meeting Intimation for Un Audited Results For The Quarter Ended 31-12-2022 HINDUSTAN BIO SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2023 inter alia to consider and approve Un audited results for the quarter ended 31-12-2022 |
Sat, 21 Jan 2023
Non-Applicability Of Large Corporate Initial Disclosure Non-Applicability Of Large Corporate Initial Disclosure |
Fri, 03 Feb 2023 |
|
|
|
|
|